Trials / Recruiting
RecruitingNCT05882773
Asian Myeloproliferative Neoplasm (MPN) Registry
Asian Myeloproliferative Neoplasm (MPN) Registry - An Asian Myeloid Working Group (AMWG) Project.
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,000 (estimated)
- Sponsor
- The University of Hong Kong · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a multinational, multicenter, prospective and retrospective, observational, cohort study of patients with myeloproliferative neoplasm.
Detailed description
This is a multinational, multicenter, prospective and retrospective, observational, cohort registry of patients with MPN. The registry mainly involves study centres in Asia including but not limited to Hong Kong, Singapore, Malaysia, Taiwan, Korea and Thailand. Clinicopathologic characteristics, cytogenetic characteristics, mutational characteristics, treatment characteristics, outcomes and survivals of Asian patients MPN diagnosed between 2010-2025 will be collected to establish clinical registry. Data on the clinicopathologic characteristics, cytogenetics, mutational profile, prognostic scoring treatment characteristics, responses to treatment, outcome and survivals will be collected through routine clinic visits and/or reviewing medical records. Data will be collected at diagnosis, and approximately every 6 months thereafter (for prospective data) and at progression until death/study termination.
Conditions
- Myeloproliferative Neoplasm
- Polycythemia Vera
- Essential Thrombocythemia
- Post-polycythemia Vera Myelofibrosis
- Post-essential Thrombocythemia Myelofibrosis
- Primary Myelofibrosis
- Primary Myelofibrosis, Prefibrotic Stage
- Primary Myelofibrosis, Fibrotic Stage
Timeline
- Start date
- 2023-05-01
- Primary completion
- 2026-05-01
- Completion
- 2026-12-01
- First posted
- 2023-05-31
- Last updated
- 2023-05-31
Locations
1 site across 1 country: Hong Kong
Source: ClinicalTrials.gov record NCT05882773. Inclusion in this directory is not an endorsement.